Company: SHPH
Filing Date: 2025-03-05
Form Type: S-1/A
Source: 0001493152-25-009106
Chunk: 49

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-05
Form: S-1/A
Chunk 49
---
 
 issuance under equity compensation plans            |           |
|:-----------------------------------------------------------|:----|:---------------------------------------------------|--------:|:----|:---------------------------------------------------------|-----:|:----|:----------------------------------------------------|----------:|
| Equity compensation plans approved by security holders     |     |                                                    | 244,439 |     | $                                                        | 1.20 |     |                                                     | 1,231,910 |
| Equity compensation plans not approved by security holders |     |                                                    |         |     |                                                          |      |     |                                                     |           |
| Total                                                      |     |                                                    | 244,439 |     |                                                          | 1.20 |     |                                                     | 1,231,910 |

*Outstanding equity incentive grants consist entirely of RSUs which automatically vest over time into an equal number of shares of common stock at no additional cost to the holder.

<div align='center'>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</div>

Unless described below, during the last two fiscal years, there were no transactions or series of similar transactions to which we were a party or will be a party, in which:

| ● | the                                                                                                                                
 amounts involved exceed or will exceed $120,000; and                                                                               |
| ● | any                                                                                                                                
 of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of any 
 of the foregoing had, or will have, a direct or indirect material interest.                                                        |

| 32 |

On December 1, 2020, the Company consolidated two loans obtained in 2018 for a total of $350,000 from Joy Dritschilo, the wife our Chief Executive Officer, which loans accrued interest at 7.5% since the date of inception, into a single loan between Mrs. Dritschilo and the Company (the “2018 Consolidated Loan”) such that, with accrued interest, the 2018 Consolidated Loan had a principal balance of $424,005.65, bore interest at a rate of 7.5% per annum, and had a maturity date of December 31, 2021. The 2018 Consolidated Loan were then extended until June 30, 2022, pursuant to an amendment to the 2018 Consolidated Loan agreement dated January 24, 2022. On July 29, 2022, the Company and Mrs. Dritschilo entered into an amendment to the 201